BRPI0410266A - cristal, composto, processo para produzir um cristal, composição farmacêutica, inibidor de quinase, e, preventivo e/ou um remédio para doenças - Google Patents

cristal, composto, processo para produzir um cristal, composição farmacêutica, inibidor de quinase, e, preventivo e/ou um remédio para doenças

Info

Publication number
BRPI0410266A
BRPI0410266A BRPI0410266-5A BRPI0410266A BRPI0410266A BR PI0410266 A BRPI0410266 A BR PI0410266A BR PI0410266 A BRPI0410266 A BR PI0410266A BR PI0410266 A BRPI0410266 A BR PI0410266A
Authority
BR
Brazil
Prior art keywords
crystal
compound
producing
pharmaceutical composition
kinase inhibitor
Prior art date
Application number
BRPI0410266-5A
Other languages
English (en)
Inventor
Mitsuru Teramoto
Naoki Tsuchiya
Hiroshi Saitoh
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33447189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410266(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of BRPI0410266A publication Critical patent/BRPI0410266A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"CRISTAL, COMPOSTO, PROCESSO PARA PRODUZIR UM CRISTAL, COMPOSIçãO FARMACêUTICA, INIBIDOR DE QUINASE, E, PREVENTIVO E/OU UM REMéDIO PARA DOENçAS". Cristais de um derivado de benzimidazol que são úteis como um agente terapêutico. Eles são cristais multiformes de ácido 4-(1-((4-metilbenzotiofen3-il)metil)benzimidazol-2-iltio)butanóico.
BRPI0410266-5A 2003-05-14 2004-05-14 cristal, composto, processo para produzir um cristal, composição farmacêutica, inibidor de quinase, e, preventivo e/ou um remédio para doenças BRPI0410266A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003135567 2003-05-14
PCT/JP2004/006887 WO2004101551A1 (ja) 2003-05-14 2004-05-14 ベンズイミダゾール誘導体の結晶及びその製造方法

Publications (1)

Publication Number Publication Date
BRPI0410266A true BRPI0410266A (pt) 2006-05-16

Family

ID=33447189

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410266-5A BRPI0410266A (pt) 2003-05-14 2004-05-14 cristal, composto, processo para produzir um cristal, composição farmacêutica, inibidor de quinase, e, preventivo e/ou um remédio para doenças

Country Status (25)

Country Link
US (1) US7649008B2 (pt)
EP (1) EP1626048A4 (pt)
JP (1) JPWO2004101551A1 (pt)
KR (1) KR20060011997A (pt)
CN (1) CN1788007A (pt)
AR (1) AR044340A1 (pt)
AU (1) AU2004238708A1 (pt)
BR (1) BRPI0410266A (pt)
CA (1) CA2523978A1 (pt)
CL (1) CL2004001034A1 (pt)
CO (1) CO5660259A2 (pt)
EC (1) ECSP056162A (pt)
IS (1) IS8177A (pt)
MA (1) MA27805A1 (pt)
MX (1) MXPA05011851A (pt)
NO (1) NO20055181L (pt)
NZ (1) NZ542978A (pt)
PE (1) PE20050203A1 (pt)
RU (1) RU2332417C2 (pt)
SA (1) SA04250117B1 (pt)
TN (1) TNSN05288A1 (pt)
TW (1) TW200505911A (pt)
UA (1) UA81493C2 (pt)
WO (1) WO2004101551A1 (pt)
ZA (1) ZA200508640B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
KR20060120601A (ko) * 2003-08-22 2006-11-27 데이진 화-마 가부시키가이샤 키마제 저해제를 유효 성분으로서 함유하는 약제
JPWO2006052026A1 (ja) * 2004-11-12 2008-05-29 帝人ファーマ株式会社 ベンズイミダゾール誘導体の酸性塩及びその結晶
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237608B1 (de) 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
AU687202B2 (en) 1994-05-31 1998-02-19 Teijin Limited Naphthalene derivative
ES2150353B1 (es) 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
TR200100047T2 (tr) 1998-07-15 2001-10-22 Teijin Limited Tiyobenzimidazol türevleri
US20040010004A1 (en) * 2000-01-17 2004-01-15 Naoki Tsuchiya Benzimidazole derivatives
EP1249450B1 (en) 2000-01-17 2007-10-10 Teijin Pharma Limited Benzimidazole derivatives as human chymase inhibitors
EP1792614A1 (en) * 2001-02-22 2007-06-06 Teijin Pharma Limited Benzo[b]thiophene derivatives
EP1298130B1 (en) * 2001-05-07 2008-08-13 Teijin Pharma Limited 3-hydroxymethylbenzo b thiophene derivatives and process for their preparation
US20040122042A1 (en) * 2001-08-24 2004-06-24 Hidenori Urata Drugs containing chymase inhibitor and ace inhibitors as the active ingredients
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r

Also Published As

Publication number Publication date
TW200505911A (en) 2005-02-16
JPWO2004101551A1 (ja) 2006-07-13
SA04250117B1 (ar) 2009-09-02
CL2004001034A1 (es) 2005-03-28
ZA200508640B (en) 2007-02-28
CA2523978A1 (en) 2004-11-25
AU2004238708A1 (en) 2004-11-25
AR044340A1 (es) 2005-09-07
IS8177A (is) 2005-12-13
UA81493C2 (en) 2008-01-10
EP1626048A4 (en) 2008-11-12
US20060293375A1 (en) 2006-12-28
NO20055181L (no) 2006-01-24
US7649008B2 (en) 2010-01-19
KR20060011997A (ko) 2006-02-06
RU2005138868A (ru) 2006-07-10
WO2004101551A1 (ja) 2004-11-25
MXPA05011851A (es) 2006-02-17
ECSP056162A (es) 2006-04-19
CN1788007A (zh) 2006-06-14
MA27805A1 (fr) 2006-03-01
PE20050203A1 (es) 2005-03-26
EP1626048A1 (en) 2006-02-15
RU2332417C2 (ru) 2008-08-27
CO5660259A2 (es) 2006-07-31
NO20055181D0 (no) 2005-11-03
NZ542978A (en) 2009-04-30
TNSN05288A1 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
SE0100568D0 (sv) Compounds
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
BR0312729A (pt) Novos derivados de indol-3-enxofre
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BRPI0413849A (pt) metanossulfonato de etiléster de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2 -il-amino]-propiÈnico e seu uso como medicamento
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
BRPI0512253A (pt) composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
BRPI0408727A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto
BR0312722A (pt) Derivados de pirazol heterobicìclico como inibidores de qinase
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
PA8571201A1 (es) Polimorfo del acido 4-[2-[4-[1-(2-etoxietil)-1h-bencimidazol-2-il]-1-piperidinil]etil]-alfa, alfa-dimetil-bencenoacetico
BR0215277A (pt) Dicetopiperazinas substituìdas como antagonistas da oxitocina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2146 DE 22/02/2012.